We are an international biotech company committed to improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, our passionate, innovative, and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, we have formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, our vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.  We are united by our core values: a passion for innovation, determination, integrity, and working as one team and respecting each other. When you work at Genmab you'll be part of a warm, fun, dynamic community seeking out and embracing the opportunity to build new and bold futures within a rapidly growing biotech company. Genmab is a place where you can be authentically you; you are empowered to innovate, build solutions, and execute; feel cared for and supported. In its totality, this makes working at Genmab an extra[not]ordinary experience. Established in 1999, we are headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S., and Tokyo, Japan.  For more information, please visit Genmab.com Disclaimer: http://bit.ly/GENDisclaimer 

Bolt Biotherapeutics

GlaxoSmithKline

BankInvest Biomedical Venture

Dansk Erhvervsinvestering

LODH Immunology Fund

Apax Partners France

Index Ventures

Genmab

Seagen is a biotechnology company that focuses on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.

Seagen

AbCellera is a technology company that specializes in antibody discovery, partnering with organizations to accelerate the development of groundbreaking biologics.

AbCellera

Tizona Therapeutics is a clinical-stage biotechnology company that is dedicated to developing first-in-class immunotherapies to treat cancer.

Tizona Therapeutics

Genmab A/S is a Danish biotechnology company founded in 1999, specializing in the creation and development of differentiated antibody therapeutics to combat cancer and other serious diseases. The company is rooted in science and inspired by patients, with a vision to transform the lives of people with cancer and other serious diseases by 2030.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Feb 24, 2024 3:00 AM	7471ab5b
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 24, 2024 3:00 AM	360377a3
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Feb 24, 2024 3:00 AM	d718dd2a
translate crunchbase fundingrounds	general
peers	general
news basic	general	Feb 24, 2024 3:00 AM	abebfd2c
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:GENMAB

Genmab A/S

Last Close

1,445.00

21/11 15:59

Market Cap

116.34B

Beta: -

Volume Today

87.56K

Avg: -